TickerFacts.

MBX Biosciences, Inc. (MBX): Shareholders' Equity

Annual figures by period end, from SEC filings.

$369.22M
As of 2025-12-31
$409.54M
As of 2026-06-30
2023-12-31: -$72.47M2024-12-31: $257.44M2025-12-31: $369.22M$369.22M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$369.22M+43.4%2026-03-12, Balance as of period end
2024-12-31$257.44Mn/m2026-03-12, Balance as of period end
2023-12-31-$72.47Mn/a2025-03-17, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
MBX Biosciences, Inc. (MBX)2025-12-31$369.22M+43.4%
Zenas BioPharma, Inc. (ZBIO)2025-12-31$242.14M-22.5%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$13.69Mn/m
Entrada Therapeutics, Inc. (TRDA)2025-12-31$306.13M-28.6%
Oncotelic Therapeutics, Inc. (OTLC)2025-12-31$262.76Mn/m
Akebia Therapeutics, Inc. (AKBA)2025-12-31$32.61Mn/m
Erasca, Inc. (ERAS)2025-12-31$325.17M-23.2%
Ironwood Pharmaceuticals Inc (IRWD)2025-12-31-$261.83Mn/m
Tango Therapeutics, Inc. (TNGX)2025-12-31$346.18M+73.5%

Compare MBX, ZBIO, XERS, TRDA side by side · Screen every company in Pharmaceutical Preparations ↗